Cargando…
Regulatory Pathway for Licensing Biotherapeutics in Mexico
Biotherapeutic products which are derived from living organisms using recombinant DNA technology significantly contribute to the progress in the treatment of life-threatening and chronic diseases. The worldwide sale of biological drugs in 2016 was near US $263,700 million. In Latin America, where mo...
Autores principales: | López-Morales, Carlos A., Tenorio-Calvo, Alejandra, Cruz-Rodríguez, Rodolfo, Sánchez y Tepoz, Julio, Belgharbi, Lahouari, Pérez-Tapia, Sonia Mayra, Medina-Rivero, Emilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167464/ https://www.ncbi.nlm.nih.gov/pubmed/30320117 http://dx.doi.org/10.3389/fmed.2018.00272 |
Ejemplares similares
-
Perspectives for licensing vaccines in Mexico
por: Padron-Regalado, Eriko, et al.
Publicado: (2022) -
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance
por: Camacho-Sandoval, Rosa, et al.
Publicado: (2020) -
Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons
por: Mejía-Calvo, Ignacio, et al.
Publicado: (2019) -
Live biotherapeutic products: the importance of a defined regulatory framework
por: Cordaillat-Simmons, Magali, et al.
Publicado: (2020) -
Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)